AG  AH  AH  AI  AJ  AJ  AV  AK  AL  AM  AN  AN  BOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO  COUNTRY  AP WO 94/22477 10/10/97 WIPO  AP WO 94/22477 10/13/94 WIPO  AP WO 94/22477 10/13/94 WIPO  AQ  AR  AR  AS  AT  AU  AV  OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)  OTHER HEMANI MMUNODEFICIENCY VIRUS TYPE 1 pp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276- ISSN: 0022-538X.  AX  CR. Acad. Sci. Paris, Sciences de la viel. Ife Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude  Lavalles, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONEF HIV-1 gp160  PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  JOURNAL OF VIRUS TYPE 1 gp14 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp14 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp14 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp14 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp14 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY AN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY AN HUMAN IMM	<u> </u>								
APPLICANT   Yutaro KANEKO, et al.	Form PTO 1449 (Modified) PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO.				
UIST OF REFERENCES CITED BY APPLICANT	Table?					09/087,513			
FILING DATE   GROUP   1632  U.S. PATENT DOCUMENTS  EXAMINER   NUMBER   DATE   NAME   CLASS   SUB   FILING DATE   CLASS   FAPROPRIATE   CLASS   SUB   FAPROPRIATE   CLASS   FAPROPRIATE   CLASS   SUB   FAPROPRIATE   CLASS   CLASS   FAPROPRIATE   CLASS   CLASS   FAPROPRIATE   CLASS   CLASS   CLASS   CLASS   FAPROPRIATE   CLASS	LIST OF REFERENCES CITED BY APPLICANT				APPLICANT				
May 29, 1998  U.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  OLASS SUB FILING DATE NAME  CLASS SUB FILING DATE (LASS IF APPROPRIATE)  AB CLASS SUB FILING DATE (LASS IF APPROPRIATE)  AC CLASS SUB FILING DATE (LASS IF APPROPRIATE)  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  COUNTRY TRANSLATION YES NO  TRANSLATION YES NO  TRANSLATION YES NO  TRANSLATION YES NO  TO THER REFERENCES (including Author, Title, Date, Perlinent Pages, etc.)  TO THER REFERENCES (including Author, Title, Date, Perlinent Pages, etc.)  TO THER REFERENCES (including Author, Title, Date, Perlinent Pages, etc.)  THE AUTHOR OF THE COUNTRY TO THE COUNTRY TO APPROVE THE DATE OF THE COUNTRY OF THE CO					Yutaro KANEKO, et al.				<del> </del>
U.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  NAME  CLASS  CLASS  FILING DATE  NAME  CLASS  CLASS  FRAPPROPRIATE  AA  AB  AC  AD  AD  AC  AD  AC  AD  AC  AD  AC  AC					FILING DATE		GROUP		
EXAMINER NUMBER DATE NAME CLASS SUB FILING DATE IN AMBER NUMBER TO DOCUMENT AND DOCUMENT AND DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO THE HUMAN INMUNDOEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A SISN. 0022-5338.  AND AND COMPONITOR THE COUNTRY TRANSLATION AND AND AND AND AND AND AND AND AND AN					May 29, 1998		1632		
INITIAL  AA  AB  AB  AB  AC  AC  AD  AC  AC  AD  AC  AC  AC  AD  AC  AC					U.S. PATENT DOCUMENTS				
AB					NAME	CLASS			
AC  AD  AE  AF  AF  AG  AG  AH  AI  AI  AI  AI  AI  AN  BOUMENT  NUMBER  DATE  COUNTRY  TRANSLATION  YES  NO  TOMER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AC  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author		AA				1			
AD  AE  AF  AG  AG  AH  AI  AI  AI  AN  AK  AK  AL  AN  AN  BOULMENT  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  TRANSLATION YES  NO  TOUTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AD  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OCHOPOLIC (Including Author, Title, Date, Per		AB							:
AE  AF  AG  AG  AH  AI  AI  AI  AI  AI  AN  AN  AN  AN  FOREIGN PATENT DOCUMENTS  NO  TRANSLATION YES NO  AD  AD  AD  AD  AD  AD  AD  AD  AD  A		AC				<del>                                     </del>	1		
AF  AG  AH  AI  AI  AI  AI  AI  AI  AN  AN  AN  BAN  AN  AN  AN  AN  AN  A		AD	1			†	<del>  </del>		
AG  AH  AI  AI  AI  AI  AN  AN  DOCUMENT NUMBER  DATE COUNTRY  TRANSLATION YES NO  OV 97/24447 10/13/94 WIPO  AQ  AP WO 94/22477 10/13/94 WIPO  AQ  AR  AR  AR  AI  AU  AV  OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD WARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION, XP000579276- ISSN: 0022-538X.  AT  CR. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 93-990, Claude Lavallee, et al., "FNGINEERING, EXPRESSION AND CHARACTER/IZATIONS HIV-1 gp160  AV  AV  AV  AV  AV  AV  AV  AV  AV  A		AE				<del> </del>	<del>                                     </del>		
AG  AH  AI  AJ  AJ  AV  AK  AL  AN  AN  AN  AN  AN  AN  AN  AN  AN		AF			<del>                                     </del>	<del> </del>	<del>                                     </del>		<del></del>
AN AI		AG	+		<del>                                     </del>	<del> </del>	<del>  </del>		
AI AJ AJ AK		<del>                                     </del>	<del> </del>			+	┝─┤		
AJ  AK  AL  AM  AN  DOCUMENT NUMBER  DATE  COUNTRY  TRANSLATION YES  NO  TRANSLATION YES  NO  AV  AV  AV  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AS  AT  AU  AV  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author, Title, Date, Pertinent Pages, etc.)  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  AV  AV  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  AV  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (Including Author)  AV  AV  AV  AV  JOURNAL OTHER PAGES, SECONDAIN (		H	<del> </del>		<del>                                     </del>	<del> </del>	├──┤		
AK  AL  AM  AN  AN  AN  AN  AN  AN  AN  AN  AN		-	<del>                                     </del>	<del></del>	<del>                                     </del>	<del> </del>	<del>                                     </del>	<del></del>	·
AL  AM  AN  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOCUMENTS  TRANSLATION YES NO  MO 97/24447 07/10/97 WIPO  AQ  AP WO 94/22477 10/13/94 WIPO  AQ  AR  AS  AT  AU  AV  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		<del></del>			<del></del>	-	<del>  </del>		
FOREIGN PATENT DOCUMENTS    DOCUMENT   NUMBER   DATE   COUNTRY   TRANSLATION   YES   NO		-	<del></del>	<del> </del>		<u> </u>	-		<del></del>
FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO  AO WO 97/24447 07/10/97 WIPO  AP WO 94/22477 10/13/94 WIPO  AR A			<del>                                     </del>	<del></del>	<del> </del>	<del> </del>			
POREIGN PATENT DOCUMENTS  DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO YES N		<del> </del>	<del>                                     </del>	<del></del>		<del>  </del>	<b>├</b>		
DOCUMENT NUMBER  DATE  COUNTRY  TRANSLATION YES NO  WO 97/24447  77/10/97  WIPO  AP WO 94/22477  10/13/94  WIPO  AR  AS  AT  AT  AU  AV  OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, etc.)  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A.  COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276  ISSN: 0022-538X.  AX  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PRISSSTENTLY SERONEGATIVE DONORS"  Date Considered  Date Considered  Date Considered  Fxaminer: Initial if reference is considered, whether brifet citation is in conformance with MPER 608: Date in the International		AIV	<u> </u>			1	L		- <u> </u>
NUMBER  AO WO 97/24447 07/10/97 WIPO  AP WO 94/22477 10/13/94 WIPO  AQ  AR  AR  AS  AT  AU  AV  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  Journal of Virology, vol. 66, No. 12, Dec. 1, 1992, pp. 6997-7004, Richard Wyatt, et al., "RELATIONSHIP OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp.120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claudé Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp.160  PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP0002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-8092, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp.120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PRIFISSISTENT'S SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether beneficial database is a conformance with MPEP 609. Draw time through stitute Metallic.				FO	REIGN PATENT DOCUMENTS		_		
AO WO 97/24447 07/10/97 WIPO  AP WO 94/22477 10/13/94 WIPO  AR  AR  AS  AS  AT  AU  AV  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579275 ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE Y3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED Pp. 9-14, "BROADLY CR	^			DATE	COUNTRY		l		
AP WO 94/22477 10/13/94 WIPO  AQ  AR  AR  AS  AS  AT  AU  AV  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  Journal of Virology, vol. 66, No. 12, Dec. 1, 1992, pp. 6997-7004, Richard Wyatt, et al., "RELATIONSHIP OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "RELATIONSHIP OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "BINGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PRISISSIENTLY SERONEGATIVE DONORS"  Date Considered  *Examiner: Initial if reference is considered, whether period citation is in conformance with MPEP 609. Date like the state of	WW.	AO	WO 97/24447	07/10/97	WIPO .			<del>- 1</del>	NO
AQ  AR  AT  AU  AV  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER SET, OTHER PAGES, etc.)	MILL	AP.	†		<del>                                     </del>				<del></del>
AX  AX  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether period citation is in conformance with MPEP 609. Draw line library in the latter of the latter	71777	AQ							
AS  AT  AU  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED P#FISISTENTLY SERONEGATIVE DONORS"  Date Considered  Date Considered  "Examiner: Initial if reference is considered, whether bernot distation is in conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance with MEEP 600: Draw line through distalled for the conformance		AR				-	<u> </u>		<del></del>
AT  AU  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AW  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  AY  AY  AY  AY  AY  AY  AY  AY  AZ  AZ		<del></del>	ļ. —	г——— <sup>—</sup>			<del> </del>		
AU  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AW  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AW  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  AY  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PRISSIFENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether print citation is in conformance with MPEP 609. Draw line through citation if feeting in the conformance with MPEP 609. Draw line through citation if feeting in the conformance with MPEP 609. Draw line through citation if feeting in the conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance with MPEP 609. Draw line through citation is in conformance.				r————					-
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AW  OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AW  OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether period citation is in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling if set in conformance with MPER 609. Draw line though stitling is not conformance with MPER 609. Draw line though stitling is not conformance with MPER 609. Draw line though stitling is not conformance with MPER 609. Draw line though stitling is not c			<del>                                     </del>	·			<u> </u>		
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  AW  Journal of Virology, vol. 66, No. 12, Dec. 1, 1992, pp. 6997-7004, Richard Wyatt, et al., "RELATIONSHIP OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276-ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP0002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY Gp120 ANTIBODIES"  AZ  Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether the cripic citation is in conformance with MPEP 609. Draw line though citation if each in the conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line though citation is in conformance with MPEP 609. Draw line the citation is in conformance with MPEP 609. Draw line the citation is in conformance wi			<del></del>	<del></del> '			-	<del></del>	
Journal of Virology, vol. 66, No. 12, Dec. 1, 1992, pp. 6997-7004, Richard Wyatt, et al., "RELATIONSHIP OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276—ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether periot citation is in conformance with MPER 609: Draw line through disting Medicine Medi		_^_			L				
AW OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A. COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276—ISSN: 0022-538X.  C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether prior citation is in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation if each in conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough citation is a conformance with MPER 609. Draw line brough c									
C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.  Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether prints diation is in conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance w	WY.	AW	COMPONENT OF T ISSN: 0022-538X.	MUNODER THE CD4 BI	FICIENCY VIRUS TYPE 1 gp120 1 INDING SITE IN THE FOURTH CO	THIRD VA ONSERV	ARIABLE 'ED REGI	LOOP T	O A 0005792 <u>76</u>
AY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"  Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether prints diation is in conformance with MPER 609: Draw line through citation if each in the conformance with MPER 609: Draw line through citation if each in the conformance with MPER 609: Draw line through citation if each in the conformance with MPER 609: Draw line through citation is in conformance with MPER 609: Draw line through citation if each in the conformance with MPER 609: Draw line through citation is in conformance with MPER 609: Dr	W:	AX	C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATIONOF HIV-1 pp. 160						
Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"  Examiner: Initial if reference is considered, whether protot diation is in conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with MPEP 609: Draw line through sitelies if each in the conformance with the	W	AY	Journal of Virology, HUMAN IMMUNODI	vol. 67, No. EFICIENCY	. 11, Nov. 1993, pp. 6897-6902, Ni	icole K. T	Back et	al "MII	ITATIONS IN
*Examiner: Initial if reference is considered, whether proof citation is in conformance with MPEP 609: Draw line through citation if each in	W-	AZ	Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIVE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PRESSTENTI & SERONICATIVE DONORS"						
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	Examiner		1/11/1	$\overline{}$		Date Con	sidered	7.9	7
the state of the s	*Examiner: Ini	tial if re	eference is considered, we considered. Include cor	hether or not	citation is in conformance with MPEP 60 with next communication to applicant.			itation if n	



	=	<del></del>		<del></del>		
Form PTO 1449 (Modified)		U.S. DEPAREMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.		
(Modified)  U.S. DEPARTMENT OF COMMERCE  PATENDARD TRADEMARK OFFICE			0010-0929-0X	09/087,513		
LIST OF REFERENCES CITED BY APPLICANT			APPLICANT			
			Yutaro KANEKO, et al.			
			FILING DATE	GROUP		
			May 29, 1998	1632		
		OTHER REFERENCES (	Including Author, Title, Date, Pertinent Pages, e	rtc.)		
Cun	AAA	DELETION OF ENVELOPE GUAGAINST CHALLENGE WITH HUMAN IMMUNODEFICIENC	Virology, May 2002, pp. 4222-4232, "EFFE LYCOPROTEIN ON CELLULAR RESPON: RECOMBINANT VACCINIA VIRUS EXPR Y VIRUS TYPE 1 ISOLATES"	SES AND PROTECTION ESSING gp160 OF PRIMARY		
nw	AAB	Dariusz Kmieciak, et al., The Jo DELETION OF THE V3 LOOO MEDIATED PATHOGENESIS <sup>1</sup>	purnal of Immunology, 1998, vol. 160, pp. 5 P OF gp120 ON CYTOTOXIC T CELL RES	676-5683, "THE EFFECT OF SPONSES AND HIV gp120-		
	AAC		•	i de		
	AAD					
	AAE					
	AAF			.=:		
	AAG					
	AAH					
	AAI					
	AAJ					
	AAK					
	AAL			 :		
	AAM					
	AAN					
	AAO					
	AAP					
	AAQ					
Examiner		Mu	Date Con	C' 1 UT		
*Examiner: Init conformance a	tial if re and not	ference is considered, whether or not considered. Include copy of this form	citation is in conformance with MPEP 609; Draw linwith next communication to applicant.	e through citation if not in		

DEC 0.4 2003 SHEET 1 OF 1

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. TRADEMAN	\$	SERIAL NO		N.	
				0010-0929-0X				4
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT  Vistors MANERO et al				, K
EST OF HEI ENERGES STEED BY AFFEIGHT			Yutaro KANEKO, et al.		CROUP		<b>.</b>	
				FILING DATE		GROUP		
				May 29, 1998		GROUP 1632		3
			<del></del>	U.S. PATENT DOCUMENTS		<del></del>	<del></del>	3
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
aup	AA	5,869,624	02/09/99	HASEL ET AL				
	AB	5,886,163	03/23/99	HASEL ET AL				_
<u> (Y</u>	AC	5,585,250	12/17/96	GARRITY ET AL				
MM	AD	5,853,724	12/29/98	GARRITY ET AL				
	AE							
	AF							
	AG						- <u>-</u>	
	AH							
	Ai							
	AJ						•	
	AK						•	7
	AL				1			$\neg$
	AM		<b> </b>					_
	AN		† ·					
i	~~							- 11
	AN		FO	REIGN PATENT DOCUMENTS	<u> </u>	<u> </u>		-
,		DOCUMENT NUMBER	FO	REIGN PATENT DOCUMENTS  COUNTRY			ANSLATION	
, Mu	AO		Ι.			TR YES	ANSLATION NO	
, WW		NUMBER:	DATE	COUNTRY		YES		
<b>M</b> W	AO	NUMBER:	DATE	COUNTRY		YES		
NW	AO AP	NUMBER:	DATE	COUNTRY		YES		
<b>WW</b>	AO AP AQ	NUMBER:	DATE	COUNTRY		YES		
NW	AO AP AQ AR	NUMBER:	DATE	COUNTRY		YES		
NW .	AO AP AQ AR AS	NUMBER:	DATE	COUNTRY		YES		
NW .	AO AP AQ AR AS AT	NUMBER:	DATE	COUNTRY		YES		
<b>WW</b>	AO AP AQ AR AS AT	NUMBER WO 95/06124	DATE 03/02/95	WIPO	t Pages e	YES		
WW)	AO AP AQ AR AS AT	NUMBER WO 95/06124	DATE 03/02/95	COUNTRY		YES X	NO	
	AO AP AQ AR AS AT AU AV	NUMBER. WO 95/06124  OTHER RE Dan R. Littman, Currer	DATE 03/02/95	COUNTRY WIPO Including Author, Title, Date, Pertinen		YES X	NO	
	AO AP AQ AR AS AT AU AV	NUMBER. WO 95/06124  OTHER RE Dan R. Littman, Currer	DATE 03/02/95	COUNTRY WIPO Including Author, Title, Date, Pertinen		YES X	NO	
	AO AP AQ AR AS AT AU AV	NUMBER. WO 95/06124  OTHER RE Dan R. Littman, Currer	DATE 03/02/95	COUNTRY WIPO Including Author, Title, Date, Pertinen		YES X	NO	HIV
	AO AP AQ AR AS AT AU AV	NUMBER. WO 95/06124  OTHER RE Dan R. Littman, Currer	DATE 03/02/95	COUNTRY WIPO Including Author, Title, Date, Pertinen	D4 Molecul	YES X	NO	
	AO AP AQ AR AS AT AU AV	OTHER RE Dan R. Littman, Currer Disease*, pp.160-179	DATE 03/02/95	COUNTRY WIPO Including Author, Title, Date, Pertinen	D4 Molecul	YES X tc.) le Role in T L	ymphocytes and in H	